SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the
kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin …

For decades, heart failure with preserved ejection fraction (HFpEF) proved an elusive entity
to treat. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have recently been shown to …

Oxidative stress and endothelial dysfunction have been shown to play crucial roles in the
pathophysiology of COVID-19 (coronavirus disease 2019). On these grounds, we sought to …

Parallel to the increasing prevalence of obesity in the world, the mortality from
cardiovascular disease has also increased. Low-grade chronic inflammation in obesity …

Background Cardiac fibrosis represents a key element in the pathophysiology of heart
failure with preserved ejection fraction (HFpEF), a condition highly prevalent amongst …

Background A comprehensive network meta-analysis comparing the effects of individual
sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without …

This systematic review and meta-analysis aimed to determine the association between the
use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors and dementia onset as well as …

Background Randomized controlled trials and real-world studies suggest that combination
therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like …

Abstract Background Circulating MicroRNAs (miRNAs) carried by microvesicles (MVs) have
various physiological and pathological functions by post-transcriptional regulation of gene …

Diabetes mellitus, a group of metabolic disorders characterized by high levels of blood
glucose caused by insulin defect or impairment, is a major risk factor for cardiovascular …